The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Avastin, while mainly used to treat cancer, works similarly to Eylea by blocking the vascular endothelial growth factor (VEGF) protein, which plays a key role in the formation of blood vessels.

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Avastin costs around £28 per injection when used off-label as an intravitreal injection for AMD, which compares to a cost of £816 for Eylea and £551 for Lucentis, according to the judicial ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Regulatory delays impacting EYLEA HD’s pre-filled syringe approval could hinder adoption. Increased market share of off-label Avastin poses a challenge to the anti-VEGF category. Analysts raised ...